Spain Healthcare Outlook Report, 2022
This report can be delivered to the clients within 24 Hours
DelveInsight’s, “Spain Healthcare Outlook 2022,” report provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in Spain. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of Spain.
As per DelveInsight analysis, National Committees transforms care delivery and makes it more affordable at national and regional health services, Health insurance providers and other payers boosts healthcare 's worth, Hospital chains introduced organizational efficiency change, Health learning centers refocused policy, activities and governance Integrated patient management agencies strengthens the quality of health care.
Spain Healthcare Outlook
Spain officially the Republic of Spain, is a sovereign island city-state in maritime Southeast Asia with 46.45 million people, distributed on a territory of 505,990 square kilometers. GDP Growth Rate in Spain averaged 0.29 percent from 1995 until 2020, reaching an all-time high of 1.60 percent in the first quarter of 2000 and a record low of -18.50 percent in the second quarter of 2020. The Spanish National Healthcare System ('Instituto Nacional de la Salud') founded on Spain's General Healthcare Act of 1986, guarantees universal coverage and free healthcare access to all Spanish nationals, regardless of economic situation or participation in the social security network.
The National Health System - NHS - is comprised by both the Central Government Administration and the autonomous regions public healthcare managements working in coordination to cover all the healthcare duties and benefits for which public authorities are legally responsible.
Spain Industry Overview Chapter
Pharmaceutical
Farmaindustria is the National Trade Association of the Spanish based pharmaceutical industry. It gathers most of the R&D based pharmaceutical companies established in the country, representing nearly 100% of prescription medicines sales in Spain. The industry researches, develops, produces and markets pharmaceuticals which relieve maladies, and cures diseases. The economic contribution of the sector holds the highest productivity rate of the pharmaceutical industry; constitutes a source of qualified, stable and diverse employment with about $ 13.5 million worth of exports each year; it is also intensive in R&D (20% of the whole industrial sector). Besides, the pharmaceutical industry is committed with the digitalization of Spanish public biomedical research with the healthcare system in continued training and updating of the knowledge base of its professionals. Farmaindustria is organized around different work areas, with the aim of developing and executing its mission: Self-Regulation, Relations with autonomous regions, Economic Department, R&D, International Affairs Department, Legal Department, Patients and Healthcare Professionals and Technical Department. 20% of the R&D investment of Spanish industry is undertaken by the pharmaceutical sector.
Medical Device
Medical device can be classified according to the intended purpose of medical devices in general, active implantable medical devices and medical devices for in vitro diagnosis. The EC market and the adoption of quality standards ISO 9000 along with the transfer to domestic laws of the various European directives governing the sector allow the free movement of healthcare technology within the European Union. A key opportunity for foreign companies to come to manufacture and market their products, equipment, devices in Spain and supply the nearly 800 hospitals that make up the National Health System. To carry out and promote that development it is necessary to invest and expand coverage and infrastructure of the healthcare technology sector and commit to the subsectors that have more impact and relevance for this digitization process in the healthcare sector: the Technology Sector and Clinical Information Systems.
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in Spain.
Spain Healthcare Assessment Chapter
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in Spain.
Spain: Market Access
Market access section of the Spain Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labeling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
The current system consists of three organizational levels:
Central (Organizacion de la Administracion Central): the Ministry of Health (Ministerio de Sanidad y Consumo), the state's central administration agency, is in charge of issuing health proposals, planning and implementing government health guidelines, and coordinating activities aimed at reducing the consumption of illegal drugs.
Autonomous Community (Organizacion Autonomica): each of Spain's 17 Autonomous Communities (Comunidades Autonomas) is responsible for offering integrated health services to the regional population through the centers, services and establishments of that community.
Local: the 'areas de salud' are responsible for the unitary management of the health services offered at the level of the Autonomous Community and are defined by taking into account factors of demography, geography, climate, socioeconomics, employment, epidemiology and culture.
Spain: PESTLE Analysis
The report covers a thorough analysis of the country through PESTLE analysis tool and gives political, economic, social, technological, legal and environmental aspects of healthcare industry.
Report Highlights
DelveInsight’s, “Spain Healthcare Outlook 2022,” report provides comprehensive insights about healthcare scenario, regulatory policies and reimbursement landscape in Spain. The report also identifies key trends in the healthcare market and provides insights into the demographic and healthcare infrastructure of the country. Along with this the report also provides a brief look into the trends and segmentation of the pharmaceutical and medical devices market of Spain.
As per DelveInsight analysis, National Committees transforms care delivery and makes it more affordable at national and regional health services, Health insurance providers and other payers boosts healthcare 's worth, Hospital chains introduced organizational efficiency change, Health learning centers refocused policy, activities and governance Integrated patient management agencies strengthens the quality of health care.
Spain Healthcare Outlook
Spain officially the Republic of Spain, is a sovereign island city-state in maritime Southeast Asia with 46.45 million people, distributed on a territory of 505,990 square kilometers. GDP Growth Rate in Spain averaged 0.29 percent from 1995 until 2020, reaching an all-time high of 1.60 percent in the first quarter of 2000 and a record low of -18.50 percent in the second quarter of 2020. The Spanish National Healthcare System ('Instituto Nacional de la Salud') founded on Spain's General Healthcare Act of 1986, guarantees universal coverage and free healthcare access to all Spanish nationals, regardless of economic situation or participation in the social security network.
The National Health System - NHS - is comprised by both the Central Government Administration and the autonomous regions public healthcare managements working in coordination to cover all the healthcare duties and benefits for which public authorities are legally responsible.
Spain Industry Overview Chapter
Pharmaceutical
Farmaindustria is the National Trade Association of the Spanish based pharmaceutical industry. It gathers most of the R&D based pharmaceutical companies established in the country, representing nearly 100% of prescription medicines sales in Spain. The industry researches, develops, produces and markets pharmaceuticals which relieve maladies, and cures diseases. The economic contribution of the sector holds the highest productivity rate of the pharmaceutical industry; constitutes a source of qualified, stable and diverse employment with about $ 13.5 million worth of exports each year; it is also intensive in R&D (20% of the whole industrial sector). Besides, the pharmaceutical industry is committed with the digitalization of Spanish public biomedical research with the healthcare system in continued training and updating of the knowledge base of its professionals. Farmaindustria is organized around different work areas, with the aim of developing and executing its mission: Self-Regulation, Relations with autonomous regions, Economic Department, R&D, International Affairs Department, Legal Department, Patients and Healthcare Professionals and Technical Department. 20% of the R&D investment of Spanish industry is undertaken by the pharmaceutical sector.
Medical Device
Medical device can be classified according to the intended purpose of medical devices in general, active implantable medical devices and medical devices for in vitro diagnosis. The EC market and the adoption of quality standards ISO 9000 along with the transfer to domestic laws of the various European directives governing the sector allow the free movement of healthcare technology within the European Union. A key opportunity for foreign companies to come to manufacture and market their products, equipment, devices in Spain and supply the nearly 800 hospitals that make up the National Health System. To carry out and promote that development it is necessary to invest and expand coverage and infrastructure of the healthcare technology sector and commit to the subsectors that have more impact and relevance for this digitization process in the healthcare sector: the Technology Sector and Clinical Information Systems.
Apart from this the report covers some latest information on COVID 19 update and future of healthcare technology in Spain.
Spain Healthcare Assessment Chapter
This chapter contains the statistical information containing, number of hospitals, number of beds, number of pharmacies, life expectancy of male and female, Immunization coverage, environmental health (PM 2.5 and CO2 Emissions), number of physicians, nurses, dentists and pharmacists, healthcare expenditure, healthcare expenditure as share of GDP, out of pocket expenditure, pharmaceutical import and export, Gross Domestic Product, Inflation, Unemployment, trade associations and trade fairs in Spain.
Spain: Market Access
Market access section of the Spain Healthcare Outlook report contains information on how to penetrate the pharmaceutical and medical device markets in terms of setting up manufacturing unit, import export licensing, regulations pertaining to patents, trademarks, clinical trials, advertising, pharmacy regulation, labeling and packaging. It also covers detail about healthcare insurance and reimbursement policy.
The current system consists of three organizational levels:
Central (Organizacion de la Administracion Central): the Ministry of Health (Ministerio de Sanidad y Consumo), the state's central administration agency, is in charge of issuing health proposals, planning and implementing government health guidelines, and coordinating activities aimed at reducing the consumption of illegal drugs.
Autonomous Community (Organizacion Autonomica): each of Spain's 17 Autonomous Communities (Comunidades Autonomas) is responsible for offering integrated health services to the regional population through the centers, services and establishments of that community.
Local: the 'areas de salud' are responsible for the unitary management of the health services offered at the level of the Autonomous Community and are defined by taking into account factors of demography, geography, climate, socioeconomics, employment, epidemiology and culture.
Spain: PESTLE Analysis
The report covers a thorough analysis of the country through PESTLE analysis tool and gives political, economic, social, technological, legal and environmental aspects of healthcare industry.
Report Highlights
- Overview of the pharmaceutical and medical device markets
- An insightful review of the reimbursement and regulatory landscape, covering the healthcare reimbursement process, regulatory agencies, and the approval processes for new drugs and medical devices
- Detailed analysis of the political and economic environment, including economic indicators, demographics, healthcare infrastructure and healthcare expenditure
- An overview of the opportunities for and challenges to growth in the healthcare market
- Spain – Healthcare Outlook
- Spain – Healthcare Assessment
- Spain – Market Access
- Spain – Healthcare Market Perspectives
- Spain – Analyst Views
- What are business strategies and trends shaping and driving the Spain healthcare market?
- What are reimbursement and regulatory policies, pharmaceutical and medical device market segments and companies likely to impact the Spain healthcare market in the future?
- How to organize sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investment and strategic partnership?
- How to identify, understand and capitalize on the opportunities and challenges in the Spain healthcare market?
- McKinsey Spain
- Anaconda BioMed
- Asphalion
- Droplite Technologies, S.L.
- GENESIS Biomed
- Histocell
- Institut de Bioenginyeria de Catalunya
- Instituto de Investigaciуn e Innovaciуn Parc Taulн
- Linear Chemicals, S.L.U.
- Transplant Biomedicals
- Universitat Aut?noma de Barcelona (UAB)
- MICROPTIC S.L.
1. KEY INSIGHTS
2. SPAIN AT A GLANCE
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. Key Reforms in Spain Healthcare Market
3.3. Healthcare Facility Administrative Structure
3.4. Governmental Healthcare Policy
3.5. Industry Overview
3.5.1. Pharmaceutical
3.5.1.1. Supply Channels
3.5.1.2. Major Players
3.5.1.3. Prescription VS OTC Drugs
3.5.2. Medical Device
3.5.2.1. Supply Chain
3.5.2.2. Major Distributors
3.6. Strategic Location
3.7. COVID-19 Update
3.8. Healthcare Technology Update
4. ASSESSMENT
4.1. Healthcare
4.1.1. Healthcare Facilities (Beds, Hospitals and Pharmacy)
4.1.2. Life Expectancy and Immunization Rate
4.1.3. Environmental Health (PM2.5 and CO2)
4.1.4. Healthcare Workforce (Physicians, Dentists and Nurses)
4.1.5. Healthcare Expenditure as share of GDP
4.1.6. Healthcare Expenditure
4.1.7. Out of Pocket Expenditure as share of current health expenditure
4.1.8. Pharmaceutical Imports and Exports
4.2. Economic
4.2.1. Gross Domestic Product
4.2.2. Inflation
4.2.3. Unemployment
4.2.4. Trade Association, Spain
4.2.5. Trade Fairs, Spain
5. MARKET ACCESS
5.1. Overview of Healthcare System Regulatory Bodies, Spain
5.2. Reimbursement Process, Spain
5.3. Health Insurance, Spain
5.4. Pricing Policies, Spain
5.5. Regulatory Landscape, Spain
5.5.1. Market Authorization for Pharmaceutical Products, Spain
5.5.2. Market Authorization for Medical Devices, Spain
5.5.3. Licensing Process for Pharmaceutical and Medical Device Manufacturing, Spain
5.5.4. Licensing Process for Pharmaceutical Exports and Imports, Spain
5.5.5. Intellectual Property Rights, Spain
5.5.5.1. Patent
5.5.5.2. Trademark
5.5.6. Clinical Trial Regulations, Spain
5.5.6.1. Pharmaceutical Clinical Trials Landscape, Spain
5.5.6.2. Medical Device Clinical Trials Landscape, Spain
5.5.7. Pharmaceutical Advertising Regulations, Spain
5.5.8. Medical Device Advertising Regulations, Spain
5.5.9. Pharmacy Regulations, Spain
5.5.10. Labeling and Packaging Regulations, Spain
6. SPAIN PESTLE ANALYSIS
7. DRIVER AND BARRIERS
8. APPENDIX
8.1. Research Methodology
8.1.1. Coverage
8.1.2. Secondary Research
9. REFERENCES
10. DELVEINSIGHT CAPABILITIES
11. DISCLAIMER
12. ABOUT DELVEINSIGHT
2. SPAIN AT A GLANCE
3. EXECUTIVE SUMMARY
3.1. Overview
3.2. Key Reforms in Spain Healthcare Market
3.3. Healthcare Facility Administrative Structure
3.4. Governmental Healthcare Policy
3.5. Industry Overview
3.5.1. Pharmaceutical
3.5.1.1. Supply Channels
3.5.1.2. Major Players
3.5.1.3. Prescription VS OTC Drugs
3.5.2. Medical Device
3.5.2.1. Supply Chain
3.5.2.2. Major Distributors
3.6. Strategic Location
3.7. COVID-19 Update
3.8. Healthcare Technology Update
4. ASSESSMENT
4.1. Healthcare
4.1.1. Healthcare Facilities (Beds, Hospitals and Pharmacy)
4.1.2. Life Expectancy and Immunization Rate
4.1.3. Environmental Health (PM2.5 and CO2)
4.1.4. Healthcare Workforce (Physicians, Dentists and Nurses)
4.1.5. Healthcare Expenditure as share of GDP
4.1.6. Healthcare Expenditure
4.1.7. Out of Pocket Expenditure as share of current health expenditure
4.1.8. Pharmaceutical Imports and Exports
4.2. Economic
4.2.1. Gross Domestic Product
4.2.2. Inflation
4.2.3. Unemployment
4.2.4. Trade Association, Spain
4.2.5. Trade Fairs, Spain
5. MARKET ACCESS
5.1. Overview of Healthcare System Regulatory Bodies, Spain
5.2. Reimbursement Process, Spain
5.3. Health Insurance, Spain
5.4. Pricing Policies, Spain
5.5. Regulatory Landscape, Spain
5.5.1. Market Authorization for Pharmaceutical Products, Spain
5.5.2. Market Authorization for Medical Devices, Spain
5.5.3. Licensing Process for Pharmaceutical and Medical Device Manufacturing, Spain
5.5.4. Licensing Process for Pharmaceutical Exports and Imports, Spain
5.5.5. Intellectual Property Rights, Spain
5.5.5.1. Patent
5.5.5.2. Trademark
5.5.6. Clinical Trial Regulations, Spain
5.5.6.1. Pharmaceutical Clinical Trials Landscape, Spain
5.5.6.2. Medical Device Clinical Trials Landscape, Spain
5.5.7. Pharmaceutical Advertising Regulations, Spain
5.5.8. Medical Device Advertising Regulations, Spain
5.5.9. Pharmacy Regulations, Spain
5.5.10. Labeling and Packaging Regulations, Spain
6. SPAIN PESTLE ANALYSIS
7. DRIVER AND BARRIERS
8. APPENDIX
8.1. Research Methodology
8.1.1. Coverage
8.1.2. Secondary Research
9. REFERENCES
10. DELVEINSIGHT CAPABILITIES
11. DISCLAIMER
12. ABOUT DELVEINSIGHT
